TABLE 1.
MICs of tebipenem against selected bacterial pathogensa
| Organism(s) | Phenotype | n | Tebipenem MIC (μg/ml) |
Ertapenem MIC (μg/ml) |
Meropenem MIC (μg/ml) |
|||
|---|---|---|---|---|---|---|---|---|
| Range | 50%/90% | Range | 50%/90% | Range | 50%/90% | |||
| Gram negative | ||||||||
| E. coli | Non-ESBL producing | 79 | ≤0.015 to 0.12 | ≤0.015/0.03 | ≤0.015 to 0.12 | ≤0.015/≤0.015 | NA | NA |
| ESBL producing | 21 | ≤0.015 to 0.12 | 0.03/0.06 | ≤0.015 to 0.5 | 0.03/0.5 | NA | NA | |
| AmpC producing | 6 | 0.03 to 0.12 | NA | 0.03 to 1 | NA | 0.03–0.06 | NA | |
| Klebsiella pneumoniae | Non-ESBL producing | 158 | ≤0.015 to 0.12 | 0.03/0.06 | ≤0.015 to 0.03 | ≤0.015/≤0.015 | NA | NA |
| ESBL producing | 50 | 0.03 to >32 | 0.03/>32 | ≤0.015 to >32 | 0.12/>32 | NA | NA | |
| ESBL producing, excluding CRE | 41 | 0.03 to 4 | 0.03/0.25 | ≤0.015 to >32 | 0.06/2 | NA | NA | |
| AmpC producing | 3 | 0.03 to 0.25 | NA | ≤0.015 to 0.25 | NA | 0.03 to 0.06 | NA | |
| CRE | 9 | 1 to >32 | NA | 8 to >32 | NA | NA | NA | |
| Proteus spp. | Non-ESBL producing | 94 | 0.03 to 0.5 | 0.06/0.12 | 0.03 to 0.5 | 0.12/0.25 | NA | NA |
| ESBL producing | 18 | 0.12 to 4 | 0.5/2 | ≤0.12 to 4 | 0.12/0.5 | 0.03 to 4 | 0.12/0.5 | |
| AmpC producing | 13 | 0.12 to 2 | 0.5/1 | ≤0.015 to 0.25 | 0.03/0.12 | 0.06 to 0.5 | 0.12/0.5 | |
| Pseudomonas aeruginosa | Wild type | 11 | 2 to 16 | 4/8 | 1 to 16 | 4/16 | 0.06 to 4 | 0.25/1 |
| Non-wild type | 45 | 4 to >32 | >32/>32 | 8 to >32 | >32/>32 | 0.5 to >32 | 16/>32 | |
| Gram positive | ||||||||
| Staphylococcus aureus | MSSA | 10 | ≤0.015 to 0.06 | 0.03/0.03 | 0.12 to 0.25 | 0.25/0.25 | 0.06 to 0.25 | 0.12/0.12 |
| MRSA | 10 | 0.5 to 32 | 2/16 | 2 to >32 | 4/>32 | 2 to >32 | 4/32 | |
| Staphylococcus epidermidis | MSSE | 10 | 0.004 to 0.03 | 0.03 | 0.015 to 0.25 | 0.25/0.25 | 0.015 to 0.12 | 0.06/0.12 |
| MRSE | 10 | 0.06 to 8 | 4/4 | 1 to >32 | 4/>32 | 0.25 to 32 | 4/16 | |
| Enterococcus faecalis | 10 | 1 to 2 | 2/2 | 8 to 16 | 8/16 | 4 to 8 | 8/8 | |
| Enterococcus faecium | 10 | 2 to >32 | >32/>32 | 16 to >32 | >32/>32 | 16 to >32 | >32/>32 | |
| Streptococcus pneumoniae | PSSP | 10 | 0.002 to 0.06 | 0.004/0.06 | 0.015 to 0.25 | 0.015/0.25 | 0.008 to 0.25 | 0.015/0.12 |
| PNSSP | 10 | 0.12 to 0.5 | 0.25/0.5 | 1 to 2 | 2/2 | 0.5 to 1 | 1/1 | |
| Streptococcus pyogenes | 20 | 0.002 to 0.004 | 0.004/0.004 | 0.004 to 0.015 | 0.015/0.015 | 0.002 to 0.008 | 0.008/0.008 | |
a
ESBL, extended-spectrum β-lactamase; CRE, carbapenem-resistant Enterobacterales; MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus; MSSE, methicillin-susceptible S. epidermidis; MRSE, methicillin-resistant S. epidermidis; PSSP, penicillin-susceptible S. pneumoniae; PNSSP, penicillin-nonsusceptible S. pneumoniae as defined by CLSI document M100 (29th edition) criteria for parenteral penicillin (nonmeningitis) MICs of ≥4 μg/ml (28); NA, not available.